Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer

Autor: Agnieszka Maj-Hes, Péter Nyirády, Zsolt Jurányi, Lukas Püllen, Tamás Fazekas, Boris Hadaschik, Tibor Szarvas, Sabina Sevcenco, Zsuzsa S Kocsis, Gero Kramer, Shahrokh F. Shariat, Viktor Grünwald, Anita Csizmarik, András Béla Hüttl
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Oncology
medicine.medical_treatment
Medizin
Docetaxel
urologic and male genital diseases
Androgen deprivation therapy
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
biology
Prostatectomy
Chromogranin A
Middle Aged
Prognosis
Survival Rate
Prostatic Neoplasms
Castration-Resistant
030220 oncology & carcinogenesis
Benzamides
Cohort
Androstenes
medicine.drug
Adult
endocrine system
medicine.medical_specialty
Urology
Enolase
Antineoplastic Agents
Adenocarcinoma
03 medical and health sciences
Internal medicine
Nitriles
Phenylthiohydantoin
medicine
Humans
Enzalutamide
Aged
Neoplasm Staging
business.industry
Proton Pump Inhibitors
Prostate-Specific Antigen
medicine.disease
030104 developmental biology
chemistry
Phosphopyruvate Hydratase
biology.protein
business
Popis: To assess chromogranin A (CGA) and neuron-specific enolase (NSE) levels and changes in these at different stages of prostatic adenocarcinoma (PCA).Overall, 1095 serum samples from 395 patients, divided into three treatment groups, were analysed; the radical prostatectomy (RP) cohort (n = 157) included patients with clinically localized PCA, while the docetaxel (DOC) and the abiraterone (ABI)/enzalutamide (ENZA) cohorts included 95 and 143 patients, respectively, with metastatic castration-resistant prostate cancer. CGA, NSE and total PSA levels were measured using the KRYPTOR method.Baseline CGA and NSE levels were higher in castration-resistant (DOC and ABI/ENZA cohorts) than in hormone-naïve, clinically localized PCA (P0.001). High baseline CGA levels were independently associated with poor overall survival in both the DOC and the ABI/ENZA cohorts, with a stronger association in the ABI/ENZA cohort. In the ABI/ENZA cohort, a50% CGA increase at 3 months was associated with poor survival, especially in patients with high baseline CGA levels.The two- to threefold higher neuroendocrine marker levels in castration-resistant compared to hormone-naïve PCA support the presence of neuroendocrine transdifferentiation under androgen deprivation therapy. Our results showed patients with high baseline CGA levels who experienced a further CGA increase during ABI and ENZA treatment had the poorest prognosis. Serum CGA levels could help in tailoring and monitoring therapy in advanced PCA.
Databáze: OpenAIRE
Externí odkaz: